Drug, bio-affecting and body treating compositions inventions 01/06

20060018826 - Biologic modulations with nanoparticles: Certain aspects of the invention relate to the use of small particles in biological systems, including the delivery of biologically active agents to cells or tissues using nanoparticles of less than about 200 nm in approximate diameter. Embodiments include collection of particles having a bioactive component, a surfactant molecule, a...

20060018827 - Positron therapy of inflammation, infection and disease: This invention provides methods for positron therapy of inflammation, infection and disease which comprise administering to a subject a positron emitter or an agent labeled with a positron emitter, wherein the positron emitter or agent binds to or is taken up by affected tissue or by cells at the site...

20060018825 - Probe for diseases with amyloid accumulation, amyloid-staining agent, remedy and preventive for diseases with amyloid accumulation and diagnostic probe and staining agent for neurofibrillary change: The present invention provides compounds having high affinity for amyloid β-protein which are for the diagnosis of diseases in which amyloid β-protein accumulates, for agents for specifically staining amyloid β-protein, and for the treatment and/or prophylaxis of diseases in which amyloid β-protein accumulates. The present invention also provides probes and...

20060018828 - Liposome-containing radiographic contrast medium and preparation method thereof: A method of pereparing a rediographic contrast medium containing liposomes is disclosed, comprising (a) dissolving a phospholipid and a sterol in a supercritical or subcritical carbon dioxide in the presence of a compound containing a hydroxyl group or a polyalkyleneoxide group, (b) adding thereto an aqueous solution containing an iodine...

20060018829 - Cellular receptors utilized as carrier agents for pharmaceutical compounds used in tumor imaging and cancer treatment: A method whereby non-immunogenic intraspecies proteins are used as carrier compounds to deliver imaging agents and pharmaceutical drugs to tumors in the human patient. This invention describes the propensity of certain solubilized cellular receptor proteins to localize in necrotic or inflamed areas of tumors but not in healthy normal tissues....

20060018830 - Gastrin releasing peptide compounds: wherein R1-R5 and FG are as defined herein (in the form complexed with a metal radionuclide or not), N—O—P is the linker containing at least one non-alpha amino acid with a cyclic group, at least one substituted bile acid or at least one non-alpha amino acid, and G is the...

20060018831 - Tf binding agent and use thereof: This invention relates to novel compounds, which bind to tissue factor and the use thereof for diagnostic and/or therapeutic purposes....

20060018832 - Methods of marking and testing pharmaceutical products: Methods of marking pharmaceutical products for use in clinical trials and for determining the origin or authenticity of the marked products are provided that use a variety of natural materials as markers. The natural materials have unique genetically controlled micromorphological structures that can be identified using enhanced visualization techniques. For...

20060018834 - Imaging sexual response: The present invention relates to methods for contrast-enhanced imaging of sexual response. In particular, the present invention relates to methods of magnetic resonance imaging (MRI), computerized X-ray tomography (CT), ultrasound, and optical imaging using contrast agents to measure blood flow during sexual response, especially female sexual response. The invention relates...

20060018833 - Method and system for screening compounds for muscular and/or neurological activity in animals: Screening methods and instrumentation for candidate pharmacological agents are applied to discover compounds with muscular and/or neurological activity. The method comprises the use of teleost fish, such as the medaka (Oryzias latipes), which may be stimulated with chemical agents or an electric field to produce, for example, seizure activity and/or...

20060018835 - Nanoparticles with inorganic core and methods of using them: An aspect of the invention includes a nanoparticle including a substantially monodisperse inorganic core with a surface and a coating substantially covering the surface of the substantially monodisperse inorganic core, wherein the coating includes of at least coating structure I, II, or III wherein the nanoparticle is substantially non-agglomerated and...

20060018836 - Method for treating human tumor cells with a newcastle disease virus strain having a p53 independent oncolytic effect: A method for treating p53-negative human tumor cells to induce apoptotic cell death thereof includes the step of infecting the tumor cells with the Herefordshire strain of Newcastle disease virus. The MOI is in the range of 100/1 to 1/200 cell/infected particle ratio....

20060018837 - Pharmaceutical compositions and methods for the prevention of drug misuse: A pharmaceutical composition including a therapeutic dose of an active ingredient susceptible of either intentional or accidental misuse by over-utilization and a sub-therapeutic dose of a compound in an amount sufficient to elicit an undesirable response if the recommended therapeutic dose of the active ingredient is exceeded....

20060018838 - Vacsularized tissue for transplantation: Tissue engineering holds enormous potential to replace or restore function to a wide range of tissues. However, the most successful applications have been limited to thin avascular tissues in which delivery of essential nutrients occurs primarily by diffusion. Pursuant to the present invention, a prevascularized, thick tissue construct is created...

20060018840 - Aerosolizable formulation comprising nicotine: An aerosolizable formulation comprises free-base nicotine, an organic acid, and a hydrofluoroalkane propellant. The organic acid is present in a mole ratio with said nicotine in a range of about 0.25:1 (organic acid:nicotine) to about 4:1 (organic acid:nicotine). The organic acid and said free-base nicotine form a nicotine salt. An...

20060018839 - Methods and compositions using cholinesterase inhibitors: The invention provides methods for treating and/or preventing Alzheimer's disease, psychiatric illnesses, encephalitis, meningitis, fetal alcohol syndrome, Karsakoff's syndrome, anoxic brain injury, cardiopulmonary resuscitation injuries, diabetes, Sjogren's syndrome, mental retardation, developmental delay, menopause, strokes, macular degeneration, neuronal loss associated with macular degeneration, sleep disorders, severe Alzheimer's disease, jet lag, post-traumatic...

20060018841 - Aav vectors for gene delivery to the lung: Methods of making and using recombinant AAV vectors and virions for gene delivery to the lung are described. The recombinant AAV virions are derived from caprine AAV and bovine AAV, both of which display tropism for lung tissue....

20060018842 - Composition and method for delivery of phytochemicals: Anti-microbial and anti-cancer phytochemicals can be delivered with a composition comprising an phytochemical, in which the composition allows the controlled release of the phytochemical upon administration of the composition to a subject. The phytochemicals can be delivered as a nutritional supplement, or for the treatment or prevention of cancer or...

20060018843 - Halitosis, gingivitis, and periodontitis treatment and preventative composition: Disclosed is a composition and method for the treatment and prevention of bad breath, halitosis, gingivitis, and/or periodontitis that contains one or more varieties of probiotic bacteria from the groups Lactobacillus, Bacillus, Escherichia, Enterococcus, Streptococcus, and Bifidobacterium, and/or a species of the yeast genus Saccharomyces. The composition may be in...

20060018844 - Botulinum toxin dental therapy for angular cheilosis: Methods for treating an angular cheilosis and/or a lip positioning abnormality by administration of a botulinum toxin to a patient....

20060018845 - Tooth whitening: wherein; R is H, C1-6 alkyl, (C1-6 alkylO)mR2, or —C(O)R1, wherein at least one R is H, one R is C1-6 alkyl or (C1-6 alkylO)mR2, and one R is —C(O)R1; R1 is C5-10 aryl or C1-6 alkyl, optionally substituted with at least one CO2H; R2 is H or C(O)R1; m...

20060018847 - Active ingredient combinations of polyhexamethylenebiguanidine hydrochloride and distearyldimethylammonium chloride and preparations comprising said active ingredient combinations: The invention is an active ingredient combination comprising polyhexamethylenebiguanidine hydrochloride and distearyldimethylammonium chloride and a cosmetic or dermatological formulation comprising polyhexamethylenebiguanidine hydrochloride and distearyldimethylammonium chloride. The invention also includes methods of fighting or preventing dermatological harm comprising applying to the skin a cosmetic or dermatological formulation comprising polyhexamethylene biguanidine hydrochloride...

20060018846 - Animo substituted hydroxyphenyl benzophenone derivatives: Described are amino substituted hydroxyphenyl benzophenone derivatives of formula (I), wherein R1, and R2 independently from each other are; C1-C20alkyl; C2-C20-alkenyl; C3-C10cycloalkyl; C3-C10cycloalkenyl; or R1, and R2 together with the linking nitrogen atom form a 5- or 6-membered heterocyclic ring; n1 is a number from 1 to 4; when n1=1,...

20060018849 - Cosmetic or dermatological preparations of the oil-in-water type: in which R1, R2 and R3, independently of one another, are chosen from the group consisting of ethyl, propyl and butyl, and R4 is a hydrogen atom or a CH3(CO) group; and a water phase, where the difference in density between the oil phase and the water phase (determinable using...

20060018848 - Photoprotective compositions comprising methyltrialkylsilanes containing a cinnamate, cinnamamide, benzalmalonamide or benzalmalonate function: Unique photoprotective compositions contain novel methyltrialkylsilanes bearing a cinnamate, cinnamamide, benzalmalonamide or benzalmalonate function, useful as sunscreens that are active in the field of UV radiation....

20060018850 - Fungicidal gel and method for controlling nail fungi: A gel formulation is combined with a fungicidal concentrate which is a liquid mixture of about 1.2 to 16 ml parts by volume of ultra pure water having an electrical resistance of 16-26 megohms, total dissolved solids of less than 0.04 parts per million and a specific conductance of less...

20060018852 - Compositions containing topical active agents and pentylene glycol: Disclosed are cosmetic and dermatological compositions containing hydrocortisone or a derivative thereof, a glycol and a thickening or gelling agent, and methods of making and using them....

20060018851 - Methods and compositions for preventing and treating hyperpigmentation of skin: Disclosed are methods for treating hyperpigmentation of skin employing topical application of compositions which comprise at least one peptide manganese complex. Also disclosed are methods wherein the composition further comprises retinol, at least one retinol derivative, or a mixture thereof and methods wherein the composition further comprises active agents selected...

20060018854 - Cosmetic compositions: The present disclosure relates to a cosmetic composition comprising at least one composite pigment, the composite pigment comprising an inorganic core at least partially coated with at least one organic coloring substance, wherein the mean gloss T0h of the composition is not less than 30....

20060018853 - Cosmetic pack preparation: A cosmetic pack preparation comprising (a) 5-20 wt % of polyvinyl alcohol and (b) 0.01-10 wt % of atitanium-titanium dioxide sinter is disclosed. The cosmetic pack preparation enables distinct identification of areas which the cosmetic composition was applied to or was peeled from and the skin cleaning effect, imparts a...

20060018855 - Cosmetic method and composition: An aqueous antiperspirant or deodorant oil in water emulsion suitable for being dispensed through a roll-on exhibiting superior consumer attributes and comprising a continuous aqueous phase containing an antiperspirant or deodorant active, an ethoxylated ether emulsifier or mixture having an average HLB of from 7 to 9 and a dispersed...

20060018856 - Siloxane polymers with quadruple hydrogen bonding units: The invention relates to the synthesis of siloxane polymers containing self-complementary quadruple hydrogen bonding groups (4H-units). The resulting polymers show unique new characteristics that result from the reversible, physical interactions between the polysiloxane chains that are based on the (supramolecular) interactions between the 4H-units. The polysiloxanes in this invention show...

20060018867 - Cosmetic composition and production thereof: It has been desired to develop a highly preservative and antibacterial cosmetic composition that can easily be applied to both emulsion and non-emulsion type cosmetics. It has also been desired to develop a method of improving a preservative and/or antibacterial effect(s) of a cosmetic composition comprising polyorganosiloxane-containing epsilon-polylysine and thereby...

20060018857 - Conditioning surface-active preparation: in which R1 is a linear or branched alkyl or alkenyl group containing 6 to 22 carbon atoms and n is a number of 1 to 50, (c) 0.005 to 1.5% by weight of at least one alkaline earth metal ion and (d) 0.1 to 3% by weight of a...

20060018858 - Skin care composition: Disclosed is a skin care composition comprising: (1) from about 0.001% to about 10% of a flavonoid compound; (2) from about 0.01% to about 15% of a vitamin B3 compound; and (3) a dermatologically acceptable oil continuous phase carrier....

20060018859 - Modified human serum albumin with reduced or eliminated affinity to chemical or biological contaminants at cys 34: A modified serum albumin is provided which has been modified at position cysteine 34 of human serum albumin, or at equivalent locations in other mammalian serum albumins, with an amino acid which lacks a sulphydryl group and will thus be less reactive with biological or chemical molecules such as trace...

20060018860 - Skin care composition: Disclosed is a composition comprising: (1) from about 0.001% to about 10% of a flavonoid compound; (2) from about 0.01% to about 15% of a vitamin B3 compound; and (3) a dermatologically acceptable single aqueous phase carrier....

20060018861 - Skin care composition: Disclosed is a skin care composition comprising: (1) from about 0.001% to about 10% of a flavonoid compound; (2) from about 0.01% to about 15% of a vitamin B3 compound; and (3) a dermatologically acceptable oil-in-water carrier comprising at least about 2% by weight of the entire composition of an...

20060018862 - Substrate based skin care device: Disclosed is a skin care device comprising: (1) a dermatologically acceptable preformed substrate and (2) a flavonoid compound, wherein the device comprises a liquid medium for delivering the flavonoid compound....

20060018863 - Novel ethylenic copolymers, compositions and methods of the same: The present disclosure relates to novel ethylenic copolymers comprising from 10% to 80% by weight, of at least one monomer of polyethylene glycol (meth)acrylate type, from 20% to 90% by weight, of at least one anionic monomer, and from 0% to 70% by weight, at least one additional nonionic hydrophilic...

20060018864 - Cosmetic preparation containing glycerylamino acid derivative: Skin care cosmetics, such as lotions, creams and milky lotions, and hair cosmetics, such as hair creams, hair conditioners, hair rinses and shampoos, being excellent in moisturizing effect, applicability, stability and safety and characterized in containing an amino acid N-glyceryl derivative produced by reacting neutral, basic or acidic α-amino acid...

20060018865 - Foaming cleansing composition: A cleansing composition for topical application containing at least one surfactant chosen from alkyl glycol carboxylic acids and their salts, and at least one surfactant chosen from monoalkyl phosphates, dialkyl phosphates and their salts. The composition has good cosmetic properties, and the foam obtained is fine and rinses off well....

20060018866 - Oil-in-water emulsified composition: (C) an acid compound selected from the group consisting of inorganic acid or an organic acid having 5 or less carbon atoms, and (D) cholesterol or phytosterol, wherein the ratio of a liquid oil component containing Component (A) in the total amount of oil phase is 5 to 90 wt...

20060018869 - Cosmetic or dermatological preparation with a content of creatine, creatinine or derivatives thereof in combination with soybean germ extract: The invention is a cosmetic or dermatological preparation with a content of an active agent combination comprising (a) at least one creatinine compound selected from the group consisting of creatinine and derivatives of creatinine; (b) at least one creatine compound selected from the group consisting of creatine and derivatives of...

20060018868 - Use of a cotton honeydew extract as active ingredient in or for preparing a cosmetic and/or pharmaceutical composition: The invention concerns the use, as active principle, in or for preparing a composition, of an efficient amount of at least one extract of cotton honeydew, the extract or the composition being designed for care of keratinous substrates. The invention also concerns a cosmetic and/or pharmaceutical composition containing said extract,...

20060018870 - Rigid polymer and method of making same: A rigid polymer has: a homopolymer of one of a polymerizable bio-derived rigid compound having two or more reactive functional groups, a derivative of the bio-derived rigid compound, a hydrolyzed substance of the bio-derived rigid compound, a derivative of the hydrolyzed substance of the bio-derived rigid compound and the substances...

20060018871 - Aptamer therapeutics useful in the treatment of complement-related disorders: The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders....

20060018872 - Poly(lactic acid) copolymer hydrogels and related methods of drug delivery: A-B-A triblock copolymers tailored to produce certain embodiments that have specific properties, such as relatively high elastic modulus. Also provided are methods of designing and synthesizing such a triblock copolymer having desired properties, such non-limiting copolymers comprising a poly(ethylene oxide) block and a block selected from at least one of...

20060018873 - Peptides of il-2 and derivatives thereof and their use as therapeutic agents: The present invention relates to new peptides of IL-2, and derivatives thereof and their use as therapeutic agents....

20060018874 - Fatty acid formulations for oral delivery of proteins and peptides, and uses thereof: Fatty acid compositions for administration of of pharmaceutical agents, such as proteins and peptides, protein and peptide conjugates, and/or cation-polypeptide conjugate complexes. In particular, the invention provides a solid pharmaceutical composition formulated for oral administration by ingestion, having from about 0.1 to about 75% w/w fatty acid component, where the...

20060018875 - Interferon compositions and methods of use thereof: The present invention provides compositions, including pharmaceutical compositions, comprising IFN-α and IFN-γ. The present invention further provides methods of treating various disorders, the methods comprising administering an effective amount of a subject composition....

20060018876 - Treatment of diseases caused by viral infection: A method of prophylactic and/or therapeutic treatment of a mammal for a disease that is caused by a Ljungan virus infection, such as Myocarditis, Cardiomyopathia, Guillain Barré Syndrome, and Diabetes Mellitus, Multiple Sclerosis, Chronic Fatigue Syndrome, Myasthenia Gravis, Amyothrophic Lateral Sclerosis, Dermatomyositis, Polymyositis, Spontaneous Abortion, Intrauterine Death, Preeclampsia, Sudden Infant...

20060018878 - Dual antigen specific t cells with trafficking ability: The present invention is directed to mammalian T cells and methods for using these T cells. More specifically, the invention relates to viral specific T cells that express an endogenous viral antigen receptor, a chimeric anti-tumor receptor and the chemokine receptor CCR7. These T cells are a source of effector...

20060018877 - Intradermal delivery of vacccines and therapeutic agents: The present invention relates to methods and devices for administration of vaccines and therapeutic agents into the intradermal layer of the skin. The methods of the present invention elicit increased humoral and/or cellular response as compared to conventional vaccine delivery methods, e.g., intramuscular route. Furthermore, the methods of the present...

20060018881 - Coordinate in vivo gene expression: Nucleic acids, including DNA constructs and RNA transcripts, capable of inducing coordinate expression of two to three cistrons upon direct introduction into animal tissues, are. bi- or tri-cistronic polynucleotides of this invention include those encoding and co-expressing HIV gene products, genes encoding antigens unrelated to HIV, and immunostimulatory gene products,...

20060018879 - Expression vectors for treating bacterial infections: The present invention is compositions and methods for producing anti-bacterial polypeptides, and for using those compositions and methods for treating diseases and conditions caused by a bacterial infection. More specifically, the compositions and methods include treating a gram-negative bacterium with a gram-positive host that produces a polypeptide effective against the...

20060018882 - Medical devices and methods for delivering compositions to cells: The present invention provides medical devices and methods for delivering compositions to cells. The compositions include an artificial viral vector, and particularly, an artificial adeno-associated virus vector. Such compositions can be useful for delivering the artificial viral vector across the blood-brain barrier....

20060018880 - Methods and compositions for delivery of an enhanced response to antigenic substrates: A novel immunostimulating delivery system is disclosed which provides for generation of a specific antibody response and specific T cell response to delivered antigens. According to the invention, the antigen or a nucleotide encoding the same is contained within, impregnated in or associated with a biocompatible collagen based carrier composition....

20060018889 - Methods and compositions for bone marrow stem cell-derived macrophage delivery of genes for gene therapy: The present invention provides an isolated nucleic acid comprising a promoter operably linked to a nucleic acid encoding a peptide or protein and/or an RNA (e.g., antisense or ribozyme), wherein the promoter comprises elements that can include, but are not limited to, a) a myeloid specific promoter element comprising a...

20060018888 - Suicidal mutant leishmania vaccine: The present invention discloses the use of a mutant Leishmania as a suicidal vaccine wherein the mutant Leishmania is responsive to external signals to become porphyric and commit suicidal cytolysis. The mutant can be selected from natural Leishmania species or constructed by genetic engineering....

20060018883 - Microbial preparation & method for preventing and curing the bacterial wilt the plant and its use: Formulations comprising bacterial of non-toxigenic strain Paenibacillus polymyxa or the cell-free filtrate obtained from its culture broth are provided as biological agents for control of plant pathogens. Particularly, the formulation of this invention is effective not only in inhibiting bacterial wilt and other plant diseases such as seedling Rhizoctonia, damping...

20060018890 - Method for preventing or treating respiratory infections and acute otitis media in infants: The present invention is directed to a novel method for preventing or treating respiratory infections and acute otitis media in infants. The method comprises the administration of a therapeutically effective amount of a Bifidobacteria strain and an adherence-promoting probiotic, such as LGG, to the infant....

20060018884 - Method for treating human tumor cells with a newcastle disease virus strain and a chemotherapeutic agent: A method for treating human tumor cells to induce apoptotic cell death thereof includes the step of infecting the tumor cells with a combination of the Herefordshire strain of Newcastle Disease Virus and a chemotherapeutic agent. The range of concentrations of chemotherapeutic agent/Herefordshire strain is in the range of 100/1...

20060018887 - Enhanced adipose tissue: An enhanced adipose tissue containing native adipose tissue and a concentrated amount of an active agent derived from adipose tissue, wherein the enhanced adipose tissue is preferably injected into the intervertebral disc of a patient suffering from degenerative disc disease....

20060018885 - Methods for increasing hsc graft efficiency: This invention demonstrates that FC function via TNF-α to affect function of HSC. FC from TNF-α deficient mice are impaired in facilitating HSC engraftment in both the syngeneic and allogeneic models. Co-incubation of FC with HSC results in significant increase in TNF-α at the mRNA and protein level, and increase...

20060018886 - Modalities for the treatment of degenerative diseases of the retina: This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells....

20060018891 - Super absorption coenzyme q10: An improved soft gelatin formulation and process methodology that increases single Coenzyme Q10 molecules presented to the absorption channels of the small intestines by providing medium chain triglycerides, Vitamin E and natural beta carotene to Coenzyme Q10 in a soft gel capsule to increase the absorption thereof....

20060018892 - Human serpin polypeptides: This invention relates to Thypin, a new member of the human serpin polypeptide family, methods of making Thypin polypeptides and using these polypeptides to treat various medical disorders and to methods of screening for compounds that agonize or antagonize Thypin polypeptide activities....

20060018893 - Method for determining modulation of p110delta activity: The invention relates to a novel lipid kinase which is part of the PI3 Kinase family. PI3 Kinases catalyze the addition of phosphate to inositol generating inositol mono, di and triphosphate. Inositol phosphates have been implicated in regulating intracellular signaling cascades resulting in alternations in gene expression which, amongst other...

20060018894 - Administration of enoxoparin sodium to patients 75 years and older with st-segment elevation myocardial infarction: Methods for treating ST-segment elevation myocardial infarction in a human patient 75 years of age or older. The methods comprise administering a dose of less than 1 mg per kg body weight, about 0.75 mg per kg of body weight, or 0.75 mg per kg of body weight of enoxaparin...

20060018898 - Antibody variants: This invention relates to an antibody which is modified version of a therapeutic antibody with affinity for a cell-surface antigen, the antibody having reduced affinity for the antigen compared with the therapeutic antibody as a result of a modification or modifications to the antibody molecule, wherein the antibody is capable...

20060018897 - Bispecific antibodies: The present invention provides compositions and methods for targeting stem cells to injured cardiac tissue....

20060018896 - Methods for treating conditions associated with lectin-dependent complement activation: In one aspect, the invention provides methods of inhibiting the effects of lectin-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MAp19 inhibitory agent effective to inhibit lectin-dependent complement activation. In some embodiments, the MAp19...

20060018895 - Murine monoclonal anti-idiotype antibody 11d10 and methods of use thereof: The present invention provides a monoclonal anti-Idiotype antibody 11D10 that elicits an immune response against a specific epitope of a high molecular weight mucin of human milk fat globule (HMFG) and a hybridoma that produces 11D10. The hybridoma that produces 11D10 was selected by specific procedures. 11D10 induces an immunological...

20060018899 - Her2 antibody composition: A composition comprising a main species HER2 antibody that binds to domain II of HER2, and an amino acid sequence variant thereof comprising an amino-terminal leader extension is disclosed. Pharmaceutical formulations comprising the composition, and therapeutic uses for the composition are also disclosed....

20060018900 - Self antigen vaccines for treating b-cell lymphomas and other cancers: A polypeptide self-antigen useful in a tumor-specific vaccine mimics one or more epitopes of an antigen uniquely expressed by cells of the tumor. The polypeptide is preferably produced in a plant that has been transformed or transfected with nucleic acid encoding the polypeptide and is obtainable from the plant in...

20060018901 - Use of antibodies in a very low dose for the vaccination against cancer: The use of an antibody directed against the cellular membrane antigen EpCAM for the production of a pharmaceutical preparation for the prophyactic and/or therapeutic active immunization against cancer is provided whereby the antibody is in an amount of 1 ng to 9 μg....

20060018902 - Antibodies to erythropoietin receptor and uses thereof: The present invention relates to antibodies and antigen-binding portions thereof that bind to and activate an erythropoietin receptor. The invention also relates to nucleic acid sequences encoding such antibodies and antigen-binding portions. The present invention further relates to methods of activating the endogenous activity of an erythropoietin receptor in a...

20060018907 - Anti-tnf antibodies and peptides of human tumor necrosis factor: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated pathologies and conditions, including ankylosing spondylitis, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods...

20060018904 - Combination therapies utilizing benzamide inhibitors of the p2x7 receptor: t

20060018906 - Methods for treating sarcoidosis using anti-tnf antibodies and fragments thereof: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of...

20060018905 - Methods for treating systemic lupus erythematosus using anti-tnf antibodies and fragments thereof: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of...

20060018903 - Tnf alpha-binding polypeptide compositions and methods: A TNF alpha-binding polypeptide composition comprises at least one of a modified heavy chain variable region polypeptide or a modified light chain variable region polypeptide that is capable of specifically binding to human TNF alpha. The modified heavy chain variable region polypeptide and the modified light chain variable region polypeptide...

20060018909 - Angiopoietin-2 specific binding agents: Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies....

20060018910 - Combination treatment for non-hematologic malignancies: The present invention relates to a therapeutic method for the treatment of non-hematologic malignancies comprising administering anti-IGF-1R antibodies, particularly human anti-IGF-1R antibodies, to a patient, in conjunction with the administration of at least one other therapeutic agent. The invention further relates to pharmaceutical compositions comprising these antibodies and methods of...

20060018908 - Compositions and methods for treating cancer: The invention features compositions and methods for treating or alleviating a symptom of cancer. The compositions and methods of the invention direct supra-lethal doses of radiation, called Hot-Spots, to virtually all cancer cell types....

20060018911 - Design of therapeutics and therapeutics: Therapeutic complexes and components of therapeutic complexes are provided herein. Also provided are methods of preparing therapeutic complexes and methods of administering therapeutic complexes....

20060018914 - Novel antibody conjugates reactive with human carcinomas: The present invention relates to novel antibodies, antibody fragments and antibody conjugates and single-chain immunotoxins reactive with human carcinoma cells. More particularly, the antibodies, conjugates and single-chain immunotoxins of the invention include: a murine monoclonal antibody, BR96; a human/murine chimeric antibody, ChiBR96; a F(ab′)2 fragment of BR96; ChiBR96-PE, ChiBR96-LysPE40, ChiBR96...

20060018912 - Snares for pathogenic or infectious agents and uses related thereto: The present invention provides a snare molecules comprising an attachment moiety (which facilitates attachment of a receptor to a cell) and a receptor for a toxic pathogenic or infectious agent, e.g., a virus. Methods of producing such snare molecules and their therapeutic and/or prophylactic uses are also provided by the...

20060018913 - Therapeutic use of anti-tf-antigen antibody: The invention is related to administration of monoclonal antibody JAA-F11 to an individual for inhibition of metastasis and/or inhibition of growth of cells which express TF-Ag, or for detection of tumors or metastatic foci which express TF-Ag. For inhibition of metastasis or inhibition of growth of cells expressing TF-Ag, the...

20060018916 - Compositions and methods for eliciting an immune response to gram-negative bacterial infections: Compositions for eliciting an immune response against Gram-negative bacterial infections and methods of making such compositions are provided. The composition comprises glycosylated pilin, the pilin being glycosylated with the O-antigen of a target Gram-negative bacteria of interest. Methods of eliciting an immune response by administration of such compositions are also...

20060018915 - Heteroclitic analogs and related methods: Heteroclitic analogs of class I epitopes are prepared by providing conservative, semi-conservative, or non-conservative amino acid substitutions at positions 3 and/or 4 and/or 5 and/or 6 and/or 7 and/or 8 and/or 9 and/or 10 of these epitopes. The analogs are useful in eliciting immune responses with respect to the corresponding...

20060018917 - Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers: A novel gene (designated 158P1D7) and its encoded protein are described. While 158P1D7 exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed in multiple cancers including set forth in Table 1. Consequently, 158P1D7 provides a diagnostic and/or therapeutic target for cancers. The 158P1D7 gene or fragment thereof,...

20060018918 - Production of stabilized conformational isomers of disease associated proteins: The present invention includes compositions and methods for the development, isolation and characterization of vaccine that include one or more isolated and purified non-native, stabilized conformational protein isomer antigens....

20060018920 - Lawsonia derived gene and related omph polypeptides, peptides and proteins and their uses: The present invention relates generally to therapeutic compositions for the treatment and/or prophylaxis of intestinal disease conditions in animals and birds caused or exacerbated by Lawsonia intracellularis or similar or otherwise related microorganism. In particular, the present invention provides a novel gene derived from Lawsonia intracellularis which encodes an immunogenic...

20060018919 - Peptide mimotopes of lipooligosaccharide from nontypeable haemophilus influenzae as vaccines: The present invention relates to peptide mimotopes of lipooligosaccharide from nontypeable Haemophilus influenzae as vaccines....

20060018921 - Histone deacetylase inhibitors and cognitive applications: The present invention relates to the enhancement of cognition in an individual by delivery of a histone acetylation regulator, such as a histone deacetylase inhibitor. The individual may have normal or poor memory, and the poor memory may be the result of a pathogenic condition or a non-pathogenic condition, such...

20060018922 - Use of recombinant bovine cd14 in the treatment and prevention of coliform mastitis in dairy cows: Studies in mice and humans indicate that membrane CD14 (mCD14) on the cell surface of monocytes, macrophages, and PMN mediates the activation of these cells by LPS. The soluble CD14 (sCD14) present in the circulation also binds to LPS and blocks LPS binding to mCD14. To determine the role of...

20060018923 - Novel human virus causing respiratory tract infection and uses thereof: The present invention provides the complete genomic sequence of a novel human coronavirus, coined as coronavirus-HKU1 (“CoV-HKU1”), isolated in Hong Kong from a patient who had a recent history of visit to Schenzhen, China. The virus belongs to the order Nidovirales of the family Coronaviridae, being a single-stranded RNA virus...

20060018924 - Hyaluronan synthase gene and uses thereof: The present invention relates to a nucleic acid segment having a coding region segment encoding enzymatically active hyaluronate synthase (HAS), and to the use of this nucleic acid segment in the preparation of recombinant cells which produce hyaluronate synthase and its hyaluronic acid product. Hyaluronate is also known as hyaluronic...

20060018925 - Compositions and methods for modulating rsv infection and immunity: Compositions and methods are provided for the treatment or prevention of RSV disease by modulating RSV infection and immunity. In particular, amino acid sequences in the RSV G glycoprotein, containing the chemokine motif defined as C-X-X-X-C (or CX3C), are identified that are essential in causing RSV infection and disease. The...

20060018926 - Noscapine derivatives as adjuvant compositions and methods of use thereof: An adjuvant composition comprising noscapine and its derivatives, for use in the treatment of tumors, cancer, as an adjuvant for vaccines....

20060018927 - Respiratory syncytial virus vaccines expressing protective antigens from promotor-proximal genes: Recombinant respiratory syncytial virus (RSV) having the position of genes shifted within the genome or antigenome of the recombinant virus are infectious and attenuated in humans and other mammals. Gene shifted RSV are constructed by insertion, deletion or rearrangement of genes or genome segments within the recombinant genome or antigenome...

20060018928 - Virus-like particle containing a dengue virus recombinant replicon: The present invention relates virus-like particle vaccine containing dengue virus recombinant replicon as its core and its preparation method. Such vaccine can efficiently express antigen in the infected tells. Because dengue virus can infect dendritic cells, it can efficiently present antigen and has immunity effects. Further, different dengue virus types...

20060018929 - Protein kinase deficient, immunologically active cmvpp65 mutants: This invention relates to mutated CMVpp65, a viral structural protein which activates cell mediated immunity in humans infected with CMV. The mutations remove undesirable protein kinase activity naturally present in the protein and make it suitable for the production of both DNA and protein vaccines. Therefore, the invention provides proteins...

20060018930 - Compositions comprising viruses and methods for concentrating virus preparations: A composition is disclosed comprising virus in a formulation comprising a polyhydroxy hydrocarbon buffered to maintain a pH in a range from about 7 to about 8.5 at a temperature in the range from about 2° C. to 27° C. Methods for concentrating and purifying virus preparations are also disclosed....

20060018931 - Therapeutic composition with a botulinum neurotoxin: The present invention pertains to pharmaceutical compositions which comprise a botulinum neurotoxin from Clostridium botulinum, the neurotoxin being free of the complexing proteins naturally present in the botulinum neurotoxin complex or being chemically modified or being modified by genetic manipulation. Moreover the pharmaceutical compositions of the instant invention have good...

20060018932 - Recombinant protein containing a c-terminal fragment of plasmodium msp-1: The invention relates to a recombinant protein fabricated in a baculovirus system, of which the essential constitutive polypeptide sequence is that of a C-terminal fragment of 19 kilodalton (p19) of the surface protein 1 (protein MSP-1) of the merozoite parasite of the Plasmodium type, particularly Plasmodium falciparum, which is infectious...

20060018933 - Novel drug delivery system: A novel modified release dosage form comprising of a high solubility active ingredient, which utilizes dual retard technique to effectively reduce the quantity of release controlling agents. Present invention can optionally comprise additionally another active ingredient as an immediate release form or modified release form. Present invention also relates to...

20060018934 - Novel drug delivery system: A novel modified release dosage form comprising of a high solubility active ingredient, which utilizes dual retard technique to effectively reduce the quantity of release controlling agents. Present invention can optionally comprise additionally another active ingredient as an immediate release form or modified release form. Present invention also relates to...

20060018936 - Core for cosmetic articles: A cosmetic product core comprises a basic core mass and solid particles dispersed therein. The basic core mass includes at least one fatty acid salt and at least one lipophilic material with a melting temperature range<50° C....

20060018938 - Foam skin cream, use of the foam skin protection cream and a process of its preparation: preparing a phase I by melting at 75° C. a mixture containing fatty acids, especially C12-C22 fatty acids, optionally unsaturated and/or polyunsaturated fatty acids, emulsifiers, coemulsifiers, such as triceteareth-4-phosphate, followed by metering it with stirring to a phase II temperature-controlled at 75° C. obtained from an aqueous mixture containing moisturizers,...

20060018939 - Method for preparing a fluid absorber: Disclosed are a fluid absorber, a method for preparing a fluid absorber, and a method for absorbing fluid from the skin. The disclosed method for preparing a fluid absorber generally comprises the steps of selecting a starch and an enzyme for hydrolysis of the starch, determining a fluid absorption optimum...

20060018935 - Odorless polyether-modified polysiloxane composition, process for the production thereof, and cosmetics containing the same: The deodorized, polyether-modified polysiloxane composition not producing a substance giving off a foul odor, while being produced or stored, which results from hydrolysis, oxidation or the like of a by-product or unreacted material and temporarily stable, a method for producing the same, and a cosmetic containing the same, wherein a...

20060018937 - Steroid kit and foamable composition and uses thereof: A composition and therapeutic kit including an aerosol packaging assembly including a container accommodating a pressurized product and an outlet capable of releasing a foamable composition, including a steroid as a foam. The pressurized product includes a foamable composition including: a container accommodating a pressurized product; and an outlet capable...

20060018940 - Stabilized antimicrobial composition: A composition is disclosed comprising a dissolvable solid containing an active oxygen compound and precursors for chlorine dioxide characterized in that when said solid weighs a total of about 5 grams it dissolves in about 3.8 liters of water at 25° C. in less than 30 minutes, thereby generating an...

20060018943 - Antimicrobial material for implanting in bones: The invention relates to an antimicrobial material for implanting in bones and for coating or producing an implant or an implantable medical device, whereby particles formed from an antimicrobial material are remotely dispersed inside a matrix material that forms a matrix when hardened. In order to improve the compatibility of...

20060018944 - Polycationic peptide coatings and methods of coating implantable medical devices: Coatings for medical devices which include polycationic peptides such as L-arginine and methods for fabricating the coatings are disclosed....

20060018942 - Polymeric microbeads having characteristics favorable for bone growth, and process including three dimensional printing upon such microbeads: The invention includes a method of three dimensional printing comprising manufacturing microbeads by an emulsion solvent extraction/evaporation process, followed by three dimensional printing onto powder layers comprising the microbeads. The invention also includes polymeric microbeads containing a bioactive substance or Active Pharmaceutical Ingredient, particularly a substance which stimulates the formation...

20060018941 - System and method for injecting liquid drug containing biological material: A method for injecting a liquid drug containing a biological material is provided, which comprises the step of injecting the liquid drug containing the biological material contained in an injector into a subject at a predetermined range of velocity....

20060018945 - Gallium inhibits biofilm formation: The present invention provides a gallium-containing composition for coating/impregnating a device or device surface to prevent biofilm growth formation. The present invention also provides a method of preventing or inhibiting biofilm growth formation. The present invention also provides methods for killing established biofilms....

20060018946 - Polymer gel containing hyaluronic acid and collagen, and its use in joints: Formulations and methods for treating joints, such as temporomandibular joint disorders, osteoarthritis of the knee, hip and other types of inflammatory joint diseases. The method involves identifying specific matrix metalloproteinases (MMPs) that may be responsible for degrading the soft tissues of the joint in question, identifying the specific component of...

20060018948 - Biodegradable implantable medical devices, methods and systems: The invention provides implantable intraluminal medical devices that are fabricated of biodegradable materials. The invention further provides methods of treatment utilizing the devices....

20060018947 - Bioresorbable nerve guide rail: A biologically resorbable nerve guide rail with a microporous guide tube of polymers of hydroxycarboxylic acids, where the porosity allows a metabolism through the tube wall, but prevents the passage of cells, and optionally several monofilaments of polymers of hydroxycarboxylic acids located in the guide tube, is characterized in that...

20060018949 - Injectable biodegradable drug delivery system: Compositions for delivering a pharmaceutically active agent to the eye, and/or for treating an ophthalmic disorder, are based on a fumarate polymer, especially a poly(propylene fumarate) polymer....

20060018950 - Body ornamentation: A pattern is applied to human skin by applying a patch in the shape of the pattern to the skin. Sun tan lotion or sun tan oil is then applied to the patch and skin. The patch is unitary, flexible, and impervious to penetration by sun tan lotion and sun...

20060018953 - Eyelid margin wipes comprising chemical means for temperature adjustment: An eyelid margin wipe comprising chemical means for adjusting the temperature of the wipe relative to the ambient temperature. The wipe is particularly useful for treatment of disorders of the eyelid or eyelid margin such as meibomian gland dysfunction....

20060018952 - Molecular reactive chitosan finishing agent used for textile: A method for making a molecular chitosan finishing agent used for textile by adding an amino-alcohol derivative and an anionic surfactant into a chitosan acetic acid with different solubilities....

20060018951 - Ph-responsive film for intravaginal delivery of a beneficial agent: The present invention provides a delivery system for the intravaginal administration of prophylactic and therapeutic agents. In one embodiment, the invention provides a pH-responsive, biocompatible film for intravaginal administration of a beneficial agent, comprising a biocompatible, hydrophilic polymer that is positively charged at a first pH and in electronically neutral...

20060018954 - Magnesium-bearing wound-covering material: The invention concerns a biocompatible and bioabsorbable wound covering material. The object of the present invention is to improve wound care by a biocompatible, biodegradable wound covering material. In that respect body-specific defense and healing mechanisms are to be assisted and antimicrobial and antiproliferative effects are to be achieved. That...

20060018955 - Method for preparing medical dressings: Healing of wounds is promoted by covering and contacting the wound with a dressing that has been infused with a suspension of a starch hydrolysate containing ascorbic acid and other components, such as collagen and alpha-tocopherol acetate. In suspension, in the infused dressing or carrier the combinations avoid the tendency...

20060018956 - Dermal application system for aminolevulinic acid-derivatives: The invention relates to a dermal application system for aminolevulinic acid-derivatives, i.e. a pressure-sensitive matrix system containing a crystalline aminolevulinic acid derivative....

20060018957 - Pharmaceutical dosage forms including rasagiline: Provided are pharmaceutical dosage forms that include rasagiline formulated and fabricated so that release of rasagiline in the stomach is retarded or inhibited....

20060018958 - Coenzyme q10 formulation and process methodology for soft gel capsules manufacturing: A formulation of Coenzyme Q10, beta-carotenes, Vitamin E, and medium chain triglycerides in rice bran oil and an optional thickener, such as bee's wax, is provided in a soft gel capsule so that a maximum of the Coenzyme Q10 is absorbed by the human body. Generally, about 60 mg of...

20060018961 - Compression formed preparation and method for manufacturing same: A compression formed preparation that rapidly disintegrates in the mouth or in an aqueous solvent, which imparts an excellent feeling during administration, and maintains a suitable hardness required for handling such as distribution and the like, and a method for manufacturing the compression formed preparation. The present invention provides a...

20060018960 - Galenic formulations of organic compounds: The present invention relates to a solid oral dosage form comprising a therapeutically effective amount of aliskiren, or a pharmaceutically acceptable salt thereof, and wherein the active ingredient is present in an amount of more than 46% by weight based on the total weight of the oral dosage form....

20060018959 - Solid drug for oral use: e

20060018963 - Extended release venlafaxine besylate tablets: Venlafaxine besylate is formulated into an extended release tablet in high loading rates by use of a coating that contains ammonio methacrylate copolymer(s)....

20060018964 - Pharmaceutical formulation and process for its preparation: The present invention relates to a multiparticulate tablet with improved gastro-protection comprising at least a pharmaceutically active substance in the form of enteric coated particles, and a mixture of tableting excipients, wherein the said mixture of excipients comprising xylitol and/or maltitol, each in a directly compressible form, a disintegrating agent,...

20060018962 - Sustained release formulation of tramadol: This invention relates to sustained release oral dosage forms comprising tramadol or a salt thereof dispersed in a matrix, wherein said matrix comprises xanthan gum....

20060018965 - Solid oral dosage form containing seamless microcapsules: This invention relates to a solid oral dosage form containing one or more pharmaceutically active ingredients solubilised or suspended in a pharmaceutically acceptable solvent or liquid phase and encapsulated in seamless controlled release microcapsules. Accordingly the pharmaceutically acceptable solvent or liquid phase may range from aqueous phase, organic solvent(s), glycols,...

20060018966 - Antimicrobial mesoporous silica nanoparticles: Methods for preparing a series of mesoporous silicates, such as room-temperature ionic liquid (RTIL)-templated mesoporous silicate particles, with various particle morphologies are provided. Methods for preparing silicate particles with antimicrobial agents within the MSN pores is also provided. The particles can be used as controlled-release nanodevices to deliver antimicrobial agents....

20060018967 - Method for treating pipelines: A method for treating and sanitizing a pipeline, such as a drinking water line, wherein the pipeline is freed from internal deposits, if any, and then internally covered with a coating material. The coating material may be easily applied to the interior of the pipeline by the disclosed methods, and...

20060018968 - Use of polyethylene glycol based fluidized polymer suspension in functional systems: An aqueous based functional system contains a stable fluid polymer suspension (FPS) thickening agent of a polysaccharide, polyethylene glycol (PEG), and hydrated thickening silica. The functional systems may be formulations of personal care excluding oral care, household care, oil field servicing fluids, Civil Engineering servicing fluids, paper coatings, construction fluids,...

20060018972 - Aqueous sustained-release drug delivery system for highly water-soluble electrolytic drugs: The present invention relates to liquid sustained release suspension dosage forms comprising ionized forms of water-soluble drugs. In particular, the invention encompasses a liquid form controlled release drug composition comprising a dispersed phase comprising an ion-exchange matrix drug complex comprising a pharmaceutically acceptable ion-exchange matrix and a water-soluble electrolytic drug...

20060018970 - Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure: The present invention provides formulations of the drug enoximone that include 40% to 80% non-ionic surfactant. Also provided a methods of treating heart failure and cardiac hypetrophy with these formulations....

20060018971 - Nucleic acid microspheres, production and delivery thereof: Nucleic acids are prepared by dissolving compounds containg them in a suitable solvent or solvent system and forming microshperes from the resulting solution. The microspheres are administered to an individual as protection from conditions where delivery of nuceic acids is useful, such as in treatment of autoimmune disease....

20060018969 - Pharmaceutical dose form and method of making the same: A method for producing a pharmaceutical dose form includes depositing a measured quantity of a first coating material on an external surface of the dose form in a patterned configuration. A measured quantity of a second coating material is deposited on the surface of the dose form in a patterned...

20060018974 - Calcium phosphate cements and methods for using the same: Methods and compositions for producing flowable compositions, e.g. pastes, that set into calcium phosphate products are provided. In the subject methods, dry reactants that include a calcium source and a phosphate source are combined with setting fluid to produce the flowable composition. A feature of the subject methods is that...

20060018973 - Composition for stimulating bone-formation and bone consolidation: The present invention relates to a composition for stimulating bone-formation and bone-consolidation, more particularly, to a composition for stimulating bone-formation and bone-consolidation by adding a material for stimulating bone-forming and bone-consolidation to the mixture of tripolyphosphate and water-soluble chitosan. The composition of the present invention can stimulate bone-formation and bone-consolidation...

20060018975 - Methods and compositions for weight management and mood enhancement: The present invention provides nutritional supplement compositions and processes for treatment using nutritional supplements that assist in weight management. One aspect of the invention comprises the inclusion in a single supplement constituent(s) that assist in reduction of a subject's cortisol level, thermogenic constituent(s), and constituent(s) that assist in stabilizing blood...

20060018976 - Nutritional supplement for osteoarthritis: The present invention relates to a method of treating osteoarthritis by administering a mineral composition in the form of a nutritional supplement, where the mineral composition may contain Smectite, Gypsum, Quartz, Feldspar, Jarosite, Kaolinite and/or Zeolite....

20060018977 - Beneficial agent delivery systems: An improved fragrance delivery system capable of providing controlled release of fragrance molecules in various consumer products is composed of a polymer having covalently bound fragrance moieties that are releasable in the form of fragrance molecules. Certain embodiments comprise globular polymer particles in which unbound fragrance molecules are occluded, absorbed...

20060018978 - Botanical compositions having hypoglycemic, hypolipidemic and antimicrobial activities for maintaining good health in normal person and diabetic patient: Botanical compositions are described having hypoglycemic, hypolipidemic and antimicrobial activity for maintaining good health in normal person and diabetic person comprising water extract of two medicinal plants, dried leaves of Malvastrum coromandelianum and/or dried stems of Coscinium fenestratum. The extracts are used separately or in combination of fixed amount or...

20060018980 - Hair restorer composition using oriental herbs: A hair restorer composition is produced by mixing 10 to 40 wt % of an Oriental herb extract of, 0.1 to 15 wt % of a viscosity control agent, 30 to 80 wt % of a surfactant, and 0.1 to 15 wt % of an oil. The Oriental herb extract...

20060018979 - Powder processing: A system is provided for pelletizing particulate raw matter having a first density, and thereafter subjecting the pellets to a milling process to obtain a powdered form of the particulate. During pelletizing steam can be added. The resulting powder is denser, or more granular or has better flow with less...

20060018981 - Sanitization process by using bacteriostatic or bactericidal products derived from vegetables: A sanitization process for obtaining a bacteriostatic or bactericidal action in an enclosed volume of space, comprising a stage of exposure of at least one bacteriostatic or bactericidal product obtained from at least one biologically grown vegetable in an amount ranging from 0.01% v/v to 3% v/v with respect to...

20060018982 - Topical application composition for preventing and treating pediculosis, method of elaboration and uses thereof: A composition of topical application for the prevention and treatment of pediculosis, elaboration method and uses of said composition. The composition comprises at least between 0.2 and 0.3% (w/v) of diallil tiosulphinate, wherein the diallil tiosulphinate is extracted from the garlic plant (Allium sativum sp). The method comprises the stages...

20060018983 - Composition containing green-yellow vegetables and light-colored vegetables: The present invention provides a composition comprising a green-yellow vegetable (e.g., broccoli, spinach, parsley, komatsuna (Brassica rapa L.), Japanese radish leaves) and a light-colored vegetable (e.g., lettuce, cabbage, celery), the composition having the following effects: (1) inhibiting the generation of blood lipid peroxide; (2) lowering blood TBARS levels or suppressing...

20060018984 - Intravaginal washing agent: An intravaginal washing agent by which the self-cleaning effect in the vagina of a patient suffering from a vaginal infection such as bacterial vaginosis, cervical chlamydiosis, trichomonal vaginitis or candidal vaginitis can be restored in the home, the invasion of bacteria, fungi, protozoa, etc. into the vagina can be prevented,...

20060018985 - Ant away: “Ant Away” is made from a petri dish that contains three (3) grams of dried bay leaves. When placed in dwellings, the object of this product will be to deter ants from dwellings. The aroma from the dried bay leaves will permeate through the ⅛″ holes drilled on the lid...

20060018986 - Extracts of decaffeinated coffee beans and orally administrable compositions comprised thereof for stimulating the sebaceous function of the skin: Orally administrable cosmetic/nutritional/pharmaceutical compositions suited for stimulating the sebaceous function of the skin, and/or for treating/preventing dry skin and/or skin aging, contain a thus effective amount of an extract of decaffeinated coffee beans, formulated into an orally administrable, physiologically acceptable medium therefor....

20060013767 - Virtual colonoscopy with radiolabeled phospholipid ether analogs: The present invention provides agents and methods for dual modality virtual colonoscopy that gives both anatomical and functional information using hybrid CT/PET scanning. In preferred embodiments, the present invention provides radiolabeled tumor-specific agents and methods for distinguishing benign polyps from malignant tumors. In further embodiments, the present invention provides compositions...

20060013768 - Injection of a radioactive dye for sentinel lymph node identification: A one-step procedure for sentinel lymph node identification and biopsy using a single compound, a radiolabeled, low molecular weight dye (e.g., 125I-labeled methylene blue). This radiolabled dye is mixed with an unlabeled, similar molecular weight dye (e.g., isosulfan or methylene blue). The mixture is injected at the time of surgery,...

20060013769 - Transdermal drug delivery formulations and method of determining optimal amounts of vasodilators therein: A method for determining and demonstrating the role of vasodilator chemical agents in the development and practice of transdermal drug delivery systems. Vasodilator chemicals applied topically dilate the blood vessels in the skin tissue, which have been shown to facilitate or inhibit systemic or skin tissue deposition of drug substances....

20060013770 - Method for screening for compounds as potential sedatives or anxiolytics: The present invention relates to a method for screening a chemical compound for its potential as a sedative or anxiolytica. The invention also relates to a drug development method and to the use of a compound as identified by the screening method for the treatment, prevention or alleviation of anxiety,...

20060013774 - Porphyrin compounds and their use in high-field mri: e

20060013772 - Method and device to recover diagnostic and therapeutic agents: The invention relates to a method and device for recovering therapeutic and diagnostic agents from the venous outflow of a tissue or organ. A method for recovering an agent includes inserting a catheter into a vascular outflow of a tissue or organ, occluding the flow of blood/fluid through the vascular...

20060013771 - Method of preparing gas-filled polymer matrix microparticles useful for echographic imaging: A method is provided to prepare gas-filled, porous microparticles having a polymer matrix interior which are useful as ultrasound echogenic contrast agents. An oil-in-water suspension is formed, both phases are frozen, then the aqueous and nonaqueous frozen phases are removed by sublimation. The resulting porous microparticles can receive a gas...

20060013773 - Biotype diets system: predicting food allergies by blood type: The invention is a diet-typing system for humans, including novel methods for diagnosis and treatment of food allergies and hypersensitivities. The diagnostic method correlates blood types (immunologically reactive antigens on RBC, skin and membranes) to four kinds of food allergies/hypersensitivities (IgE antibodies, IgG antibodies, T-cells, and Lectins). The results are...

20060013776 - Methods and compositions for treating benign gynecological disorders: An improvement in a method of treating benign gynecological disorders is described. In the method, treatment of a benign gynecological disorder with a composition comprised of a gonadotropin releasing hormone (GnRH) compound and an estrogenic compound, and optionally, an androgenic compound, is extended to premenopausal women who are not receiving...

20060013777 - Novel treatment for cough: The invention discloses the existence of cannabinoid receptors in the airways, which are functionally linked to inhibition of cough. Locally acting cannabinoid agents can be administered to the airways of a subject to ameliorate cough, without causing the psychoactive effects characteristic of systemically administered cannabinoids. In addition, locally or systemically...

20060013775 - Use of ppar activators for the treatment of pulmonary fibrosis: An activator of PPAR gamma is useful for the treatment of pulmonary fibrosis....

20060013778 - Method and composition for preventing tooth hypersensitivity when using passive bleaching agents: Dental bleaching compositions, for example in the form of liquids, gels, creams, pastes and ointments, comprising a peroxide releasing compound and from 1% to 35% by weight of a potassium-containing compound such as potassium nitrate, wherein the potassium nitrate is present in a safe and effective amount to prevent tooth...

20060013779 - Breath freshening and oral cleansing product with magnolia bark extract in combination with surface active agents: An oral composition for oral cleansing, breath freshening, and anti-microbial benefits includes Magnolia Bark Extract in combination with a surface active agent. The effectiveness of Magnolia Bark Extract in inhibiting biofilm formation in the oral cavity is increased by a synergistic combination of the Magnolia Bark Extract with a surface...

20060013780 - N,n'-dialkyl derivatives of polyhydroxyalkyl alkylenediamines:

20060013781 - Method and composition for producing enhanced fingernails: Method and compositions for strengthening, surface smoothing and thickening finger and toe nails by forming insoluble calcium phosphate materials within and on the surface of the keratin matrix of the nail. These insoluble calcium phosphate materials are developed by the application of solutions of calcium phosphate monobasic from various cosmetically...

20060013782 - Use of active extracts to improve the appearance of skin, lips, hair and/or nails: There is provided a composition having at least one of the following active extracts Butea frondosa, Naringi crenulata, Stenoloma chusana, or any combinations thereof. There is also provided a composition having at least one of the following additional extracts Azadirachta indica, Glycyrrhiza glabra linn., Morinda citrifolia, tomato glycolipid or any...

20060013783 - Fine o/w emulsion: The present invention relates to a composition containing lipophilic phase (A), an emulsifying system (B), and an aqueous phase (C) that is preferably suitable for topical use, in particular cosmetic and/or dermatological use, in the form of a fine oil-in-water emulsion that is rich in oil and can be obtained...

20060013788 - Cosmetic composition for caring for or making up keratin materials, comprising at least one polyester, and method of use thereof: The present disclosure relates to a cosmetic composition, for caring for or making up keratin materials, comprising, in a cosmetically acceptable medium, i) at least one polyester derived from the esterification, with a polycarboxylic acid, of an aliphatic hydroxycarboxylic acid ester comprising at least two hydroxyl groups and ii) at...

20060013787 - Oil-rich o/w emulsion: The present invention relates to a composition for topical application in the form of an oil-in-water emulsion, wherein it contains: a lipophilic phase (A) an emulsifying system (B) an aqueous phase (C), one or more fillers having an oil uptake greater than or equal to 75 ml/100 g, the emulsifying...

20060013786 - Skin preparation for external use: An external preparation for skin is provided which can be readily applied to the skin surface in a uniform manner, is excellent in effectiveness and storage stability, and has a pH of 2.0 or less. More specifically, the external preparation for skin of the present invention comprises one kind or...

20060013791 - Cosmetic composition comprising a defined silicone polymer and a film former: Cosmetic makeup and/or care compositions for application to the skin, lips and/or epidermal derivatives may exhibit improved staying power, satisfactory or improved gloss and improved comfort. The cosmetic compositions may include a film former and a silicon polymer....

20060013790 - Cosmetic composition comprising a defined silicone polymer and a gelling agent: The present invention relates primarily to a cosmetic makeup and/or care composition intended for application to the skin, lips and/or epidermal derivatives, comprising a particular silicone polymer, a liquid fatty phase and a gelling agent for said liquid fatty phase....

20060013789 - Cosmetic composition with improved staying power: Cosmetic makeup and/or care compositions for application to the skin, lips and/or epidermal derivatives, may include silicone polymers and hydrocarbon ester oils with low molecular weight....

20060013792 - Solid water-in-oil cosmetic emulsion: Disclosed is a solid water-in-oil emulsion comprising an aqueous phase emulsified with at least one emulsifying surfactant in a fatty phase comprising at least one ester oil and at least one wax, wherein the at least one ester oil is present in an amount greater than the at least one...

20060013793 - Solid water-in-oil cosmetic emulsion: Disclosed herein is a solid water-in-oil emulsion comprising an aqueous phase emulsified in a fatty phase comprising at least one ester oil and at least one wax, and at least one silicone surfactant comprising at least one polyhydroxylated chain or at least one alkyl dimethicone copolyol chosen from C8-C22 alkyl...

20060013794 - Cosmetic or pharmaceutical composition comprising peptides with the sequences arggly-ser: The invention relates to the use of at least one peptide, with the sequence (AA)n-Arg-Gly-Ser-(AA)n, where (AA) is any amino acid or a derivative thereof and n=0 to 3, as an active ingredient in or for the preparation of a cosmetic and/or dermatological and/or pharmaceutical preparation. The invention also relates...

20060013795 - Composition for hair treatment: The present invention pertains to a hair treatment composition that contains (a) a specific long-chain acylsulfonate type of anionic surfactant (such as an N-stearoyl-N-methyltaurine salt), (b) a higher alcohol, (c) an anionic polymer, and (d) a reducing agent or an oxidant, in which the combined amount of component (a) and...

20060013784 - Novel dimercaptoamides, compositions comprising them as reducing agents, and processes for permanently reshaping keratin fibers therewith: The present disclosure relates to specific dimercaptoamides, reducing compositions for permanently reshaping keratin fibers comprising the dimercaptoamides, for instance, human keratin fibers such as the hair; and processes for reshaping keratin fibers comprising the application of said reducing compositions. The present disclosure also relates to processes for preparing the dimercaptoamides....

20060013785 - Hairstyling gels with light protective action for skin and hair: The hairstyling agent in gel form contains a combination of at least one gel former, more than two percent by weight of at least one UV filter and at least one hair-fixing polymer. The hairstyling gel preferably is in optically clear form and can simultaneously have hair fixing action, light...

20060013796 - Hair and/or scalp treatment composition: Tulsi oil or a component compound thereof and a synthetic antimicrobial agent are capable of exhibiting a synergistic antimicrobial activity and are therefore useful in the manufacture of a composition for treating and/or preventing dandruff. A hair and/or scalp treatment composition comprises tulsi oil and a metal pyrithione, wherein the...

20060013797 - N-maleimidyl polymer derivatives: The invention is directed to multi-functional N-maleimidyl polymer derivatives comprising a water soluble and non-peptidic polymer backbone having a terminal carbon, such as a poly(alkylene glycol), the terminal carbon of the polymer backbone being directly bonded to the nitrogen atom of a N-maleimidyl moiety without a linking group therebetween. The...

20060013798 - Bis-quaternary ammonium salt corrosion inhibitors: wherein R7, R11 and R12 are independently selected from C1-C18 alkyl; R8, R9, R10 and R15 are independently selected from C8-C18 alkyl and C8-C18 alkenyl; R13 is C1-C4 alkyl; R14 is C2-C4 hydroxyalkyl; and R11 is selected from C2-C4 hydroxyalkyl, C2-C4 aminoalkyl and groups of formula —CH2)rNHC(O)R15 are effective inhibitors...

20060013799 - Multimeric vla-4 antagonists comprising polymer moieties: Disclosed are conjugates which bind VLA-4. Certain of these conjugates also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such conjugates are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease,...

20060013800 - Stable immunogenic product comprising antigenic heterocomplexes: A stable immunogenic product for the induction of antibodies against one or more antigenic proteins in a subject, characterized in that it comprises proteinaceous immunogenic heterocomplexes which are formed by associations between (i) antigenic protein molecules and (ii) proteinaceous carrier molecules and in that less than 40% of the antigenic...

20060013801 - Prevention of and therapy for radiation toxicity of normal tissues using drugs which block il-1 activity: A method for the prevention of and therapy for radiation pneumonitis, dermatitis, soft tissue fibrosis and central nervous system toxicity in patients undergoing therapeutic radiation. In addition, the invention provides for pre-treatment of those responding to nuclear bio terrorism or other nuclear or radiological accidents. Thus, with the present invention,...

20060013802 - Techniques to treat neurological disorders by enhancing the presence of anti-inflammatory mediators: Methods and devices to enhance anti-inflammatory effects in the CNS to treat neurological, neurodegenerative, neuropsychiatric disorders, pain and brain injury are described. Anti-inflammatory enhancing agents that target IL-10 production and signal transduction pathways are discussed. Devices described include therapy delivery devices comprising a reservoir capable of housing an anti-inflammatory enhancing...

20060013803 - Modified dendritic cells: Infection of a dendritic cell with a lentivirus impairs the dendritic cell's ability to act as an antigen presenting cell that polarizes a naïve T cell to develop along the Th1 pathway. This impairment is restored by infecting dendritic cells with lentiviruses containing vectors encoding IL-7, IL-12, and siRNA targeting...

20060013805 - Transgenic circulating endothelial cells: A process is provided for expanding the population of endothelial cells obtained from peripheral blood which can be transformed with a vector comprising a DNA sequence encoding a preselected bioactive polypeptide. The resulting transgenic endothelial cells are useful to biocompatibilize implantable medical devices or can be used directly, as for...

20060013806 - Probiotics in primary prevention of atopic diseases: The present invention is in the field of prophylaxis of allergies, and relates specifically to primary prevention of atopic diseases by administering probiotic bacteria, beneficial microbes of the healthy gut flora, pre- and postnatally to children at high risk of atopic diseases....

20060013804 - Modulation of stem cell differentiation by modulation of caspase-3 activity: Methods of directing stem cell fate for therapeutic purposes through the deliberate manipulation of caspase-3 activity are provided. The use of modulators of caspase-3 activity to modulate stem cell differentiation is described including activators and/or effectors of caspase-3, which can be used to induce stem cell differentiation, and inhibitors of...

20060013807 - Rapidly disintegrating enzyme-containing solid oral dosage compositions: The present invention relates to rapidly disintegrating solid oral dosage forms having an effective amount of an enzyme and a superdisintegrant....

20060013808 - Treatment for asthma: A method for the treatment of asthma is disclosed. The method comprises administration of an antibody, polypeptide or other molecule recognizing VLA-4, a protein expressed on the surface of certain leukocytes such as eosinophils....

20060013810 - Humanized fcgammariib-specific antibodies and methods of use thereof: The present invention relates to humanized FcγRIIB antibodies, fragments, and variants thereof that bind human FcγRIIB with a greater affinity than said antibody binds FcγRIIA. The invention encompasses the use of the humanized antibodies of the invention for the treatment of any disease related to loss of balance of Fc...

20060013809 - Immunotoxin derived from a recombinant human autoantibody and method of using thereof: The invention is directed to an immunotoxin directed at fetal AchR, wherein the immunotoxin may comprises a human Fab fragment based on a human autoantibody or human combinatorial cDNA library and may be a pseudomonas exotoxin A-based single chain Fv IT (35-scFV-ETA). The invention is further directed to method of...

20060013811 - Methods of treating ige-associated disorders and compositions for use therein: The present invention provides methods of treating IgE-associated disorders and compositions for use therein. The methods are particularly useful in treatment of allergies and allergy-related disorders. The methods generally comprise administering an IgE inhibitor (such as anti-IgE antibody) and an antigen and/or immunostimulatory polynucleotide sequence (ISS). These combination methods offer...

20060013812 - Pharmaceutical composition comprising factor vii polypeptides and protein c inhibitors: The present invention relates to a composition comprising factor VII or a factor VII-related polypeptide and a protein C inhibitor, and the use thereof for treating bleeding episodes....

20060013813 - Proteins and nucleic acids encoding same: Disclosed herein are nucleic acid sequences that encode novel polypeptides. Also d